795306-91-1

Upstream product

• 1011265-03-4 4R-(4-benzyloxyphenyl)-3-(4-fluorophenyl)-2-oxo-oxazolidine-5S-carboxylic acid 
• 1206694-75-8 4-(2-aza-2-(4-fluorophenyl)vinyl)-1-benzyloxybenzene 
• 795306-87-5 (2S,5R,6S)-2-[(2R,3S)-2-(4-benzyloxyphenyl)-1-(4-fluorophenyl)-4-oxocyclobutoxy]-2,4,5-trimethyl-6-phenylmorpholin-3-one 
• 795306-89-7 (2S,3R)-3-(4-benzyloxyphenyl)-3-(4-fluorophenyl)-2-hydroxypropionic acid methyl ester 
• 795306-88-6 (3S,4R)-2-(4-benzyloxyphenyl)-1-(4-fluorophenyl)-3-hydroxyazetidin-2-one 
• 795306-90-0 (4R,5S)-4-(4-benzyloxyphenyl)-3-(4-fluorophenyl)-2-oxooxazolidine-5-carboxylic acid methyl ester 

Downstream Products

• 869588-19-2 (4R,5R)-4-(4-benzyloxyphenyl)-3-(4-fluorophenyl)-5-[(E)-3-(4-fluorophenyl)-3-oxopropenyl]oxazolidin-2-one 
• 869588-20-5 (4R,5R)-4-(4-Benzyloxy-phenyl)-3-(4-fluoro-phenyl)-5-[3-(4-fluoro-phenyl)-3-oxo-propyl]-oxazolidin-2-one 
• 1048011-24-0 (4R,5S)-4-(4-(benzyloxy)phenyl)-5-((4-fluorophenoxy)methyl)-3-(4-fluorophenyl)oxazolidin-2-one 
• 1048011-28-4 ((4R,5S)-4-(4-(benzyloxy)phenyl)-3-(4-fluorophenyl)-2-oxooxazolidin-5-yl)methyl 4-fluorophenylcarbamate 
• 1048011-86-4 C₃₁H₂₄F₂N₄O₃ 
• 1048011-85-3 C₃₁H₂₅FN₄O₃ 
• 1048011-87-5 C₃₁H₂₅FN₄O₃ 
• 1048011-34-2 1-(4-fluorophenyl)-3-(((4R,5R)-3-(4-fluorophenyl)-4-(4-hydroxyphenyl)-2-oxooxazolidin-5-yl) methyl)urea 
• 1048011-45-5 (4R,5R)-3-(4-fluorophenyl)-5-((4-(4-fluorophenyl)-1H-1,2,3-triazol-1-yl)methyl)-4-(4-hydroxyphenyl)oxazolidin-2-one 
• 1048011-43-3 (4R,5R)-3-(4-fluorophenyl)-4-(4-hydroxyphenyl)-5-((4-phenyl-1H-1,2,3-triazol-1-yl)methyl)oxazolidin-2-one 
• 1048011-49-9 (4R,5R)-3-(4-fluorophenyl)-4-(4-hydroxyphenyl)-5-((5-phenyl-1H-1,2,3-triazol-1-yl)methyl)oxazolidin-2-one 
• 1048011-36-4 N-(((4R,5R)-3-(4-fluorophenyl)-4-(4-hydroxyphenyl)-2-oxooxazolidin-5-yl)methyl)benzamide 
• 1011265-06-7 C₂₄H₂₂FNO₆S 
• 1011265-07-8 (4R,5R)-5-(azidomethyl)-4-(4-(benzyloxy)phenyl)-3-(4-fluorophenyl)oxazolidin-2-one 

Relevant academic research and scientific papers

Oxazolidinones and their use as hypocholesterolemic agents

The present invention relates to novel hypocholesterolemic compounds of formula I useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels as well as to pharmaceutical compositions comprising said compounds alo

Substituted oxazolidinones as novel NPC1L1 ligands for the inhibition of cholesterol absorption

Cholesterol absorption inhibition (CAI) represents an important treatment option for hypercholesterolemia. Herein, we report the design and evaluation of a series of substituted oxazolidinones as ligands for the Niemann Pick C1 Like 1 (NPC1L1) protein, a

Heterocyclic ring scaffolds as small-molecule cholesterol absorption inhibitors

Enantio- and diastereoselective syntheses of a substituted oxazolidinone, isoxazoline and pyrazoline as β-lactam surrogates are described. The substituted heterocycles were designed to incorporate side chains closely resembling those found in the β-lactam cholesterol absorption inhibitor ezetimibe (1). Additionally, the in vitro inhibitory efficacy of the novel compounds as cholesterol absorption inhibitors is reported using a brush border membrane vesicle assay. The Royal Society of Chemistry 2005.